- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02651688
A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
June 18, 2019 updated by: Repros Therapeutics Inc.
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism [confirmed morning testosterone (T) ≤300 ng/dL] following a 6 month diet and 15 month exercise program.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
To compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T≤300 ng/dL) following a 6 month diet and 15 month exercise program.
Participants must not have been treated with testosterone products in the 6 months prior to the study and must not ever have used testosterone products for a year or longer.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Albany, New York, United States, 12208
-
Garden City, New York, United States, 11530
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
-
-
Utah
-
Riverton, Utah, United States, 84065
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Overweight (Body Mass Index (BMI) 30 to 42 (kg/m^2) inclusive) males age 18 to 60 inclusive.
- Waist circumference ≥ 40 inches (101.6 cm).
- Previously or concurrently diagnosed as having secondary hypogonadism.
- Must have 2 morning testosterone assessments at Visit 1, collected before 10 AM, 2-4 days apart, and both of which must be ≤ 300 (ng/dL).
- Luteinizing hormone (LH) >1.4 and < 9.4 milli International units per milliliter (mIU/mL) (at Visit 1 only).
- Glycated hemoglobin A1c (HbA1c) ≤7.5.
- Stable weight for last 3 months (+/- 10 pounds).
- Participant lives or works within 10 miles of the gym that will be used for the study.
- Must be fit enough to participate in the fitness program.
- Ability to complete the study in compliance with the protocol requirements.
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Any use of testosterone products (injectable, pelleted, transdermal or sublingual) in the 6 months prior to the study or any prior use of testosterone products for 12 months or longer at any time.
- Use of testosterone, Clomid, 5α-reductase inhibitors, human chorionic gonadotropin (hCG), androgen, estrogen, anabolic steroid, dehydroepiandrosterone (DHEA), or herbal hormone products during the study.
- Use of Clomid in the past year.
- Known hypersensitivity to Clomid.
- Allergy to soy, peanuts or latex.
- Chronic use of glucocorticoids (chronic use of inhaled or topical glucocorticoids is acceptable).
- History of drug abuse or chronic narcotic use including methadone.
- A recent history of alcoholism or illegal substance or steroid abuse (<2 years) or presence of moderate alcohol use (>21 drinks per week).
- Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.
- A hematocrit >54%.
- Presence or known history of hyperprolactinemia with or without a tumor (prolactin >20 ng/mL).
- Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a prostate specific antigen (PSA)>3.6.
- Current or history of breast cancer.
- Uncontrolled hypertension based on the Investigator's assessment at screening.
- History of bulimia nervosa or binge eating.
- Participant has (had) a lap band or undergone gastric bypass surgery.
- Participant has celiac disease or gluten intolerance.
- Participant has Type I diabetes.
- Participant has any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study.
- Enrolled and randomized (if applicable) in a previous enclomiphene study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Enclomiphene 12.5 mg
Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
|
Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
|
Experimental: Enclomiphene 25 mg
Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
|
Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
|
Placebo Comparator: Placebo
One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
|
One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Lean Body Mass (LBM) at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
LBM was assessed using dual-energy X-ray absorptiometry (DXA).
A positive change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Body Strength (Chest Press Weight) at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press.
A positive change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Body Strength (Leg Press Weight) at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press.
A positive change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter LH measured in milli-International Units per milliliter (mIU/mL).
A positive change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Testosterone (T) Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter T. A positive change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter DHT.
A positive change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Estradiol (E2) Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter E2.
A positive change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
The T:E2 ratio was calculated as the value of T/value of E2 using the same units.
A positive change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
The DHT:T ratio was calculated as the value of DHT/value of T using the same units.
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter HbA1c.
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Glucose Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter Glucose.
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter CRP.
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter IL-6.
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-α) Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter TNF-α .
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Leptin Level at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter leptin.
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
The HOMA-IR is the product of the blood Glucose and Insulin levels, divided by a constant.
HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (μU/mL) × fasting plasma glucose (mmol/L)/22.5.
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
Quantose-IR is a laboratory-developed test that assesses insulin resistance.
Quantose-IR score is based on a linear regression algorithm utilizing the quantitative measures (natural log transformed) of alpha-hydroxybutyrate, oleate, linoleoylglycerophosphocholine and insulin and was designed to estimate the natural log of insulin-induced glucose infusion rate normalized by whole body mass.
The algorithm score is converted to the Quantose-IR score within a range of 1-120 by an arithmetic calculation where higher scores denote greater insulin resistance.
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Body Mass Index (BMI) at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
BMI is calculated as weight (kg)/height(cm^2).
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Waist Circumference at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Change From Baseline in Weight at Week 48
Time Frame: Baseline (Day 0) to Week 48
|
A negative change from Baseline indicates improvement.
|
Baseline (Day 0) to Week 48
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2016
Primary Completion (Actual)
May 2, 2017
Study Completion (Actual)
May 2, 2017
Study Registration Dates
First Submitted
January 7, 2016
First Submitted That Met QC Criteria
January 8, 2016
First Posted (Estimate)
January 11, 2016
Study Record Updates
Last Update Posted (Actual)
June 27, 2019
Last Update Submitted That Met QC Criteria
June 18, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Hypogonadism
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Estrogen Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Clomiphene
- Enclomiphene
- Zuclomiphene
Other Study ID Numbers
- ZA-205
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Enclomiphene
-
Repros Therapeutics Inc.CompletedEffect of Treatment on Bone Mineral DensityUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedDrug-drug InteractionUnited States
-
Repros Therapeutics Inc.CompletedType 2 Diabetes Mellitus | Secondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedPharmacokinetics | TolerabilityUnited States
-
Repros Therapeutics Inc.Completed
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedSecondary HypogonadismUnited States